94% Lower Risk of Heart Disease! Lepodisiran From Eli Lilly Significantly Reduces Risk Factor According to its Phase 2 Results!
Reading Time: 4 minutes
The pharmaceutical company Eli Lilly and Company (LLY) published a report on Sunday, March 30, 2025, detailing the results of its Phase 2 study for its siRNA-based drug candidate Lepodisiran. According to the positive study results, the drug shows a 94% lower concentration of a genetically determined risk factor in adult patients with heart disease who received the highest test dose of the drug candidate. ALPACA is a Phase 2 study for its drug Lepodisiran Eli Lilly is currently conducting a Phase 2 study called ALPACA for its drug Lepodisiran....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
